GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...
Malaysiakini16h
GSK's respiratory syncytial virus vaccine approved in M'sia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
cilisos.my1d
GSK’s Arexvy vaccine for RSV is approved for Malaysian seniors
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
'A really serious respiratory virus:' What you need to know about RSV and new vaccines
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
What you need to know about RSV and new vaccines in Ontario
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I
"Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I" was originally created and published by ...
Managed Healthcare Executive2d
RSV Vaccine Keeps Older People Out of the Hospital
Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...
FierceBiotech2d
Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1
The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...
The Financial Times2d
GSK’s ex-vaccines chief says its jab for a flu-like virus is too expensive
The first RSV vaccines were approved in the US in May last year. GSK’s Arexvy vaccine generated more than $1bn in sales in ...
The Lancet2d
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year ...
infectiousdiseaseadvisor.com5d
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...